Alan Wayne Partin
#94,687
Most Influential Person Now
Alan Wayne Partin's AcademicInfluence.com Rankings
Alan Wayne Partinengineering Degrees
Engineering
#2319
World Rank
#3210
Historical Rank
Biomedical Engineering
#54
World Rank
#54
Historical Rank
Alan Wayne Partinphilosophy Degrees
Philosophy
#3569
World Rank
#5736
Historical Rank
Logic
#1249
World Rank
#1946
Historical Rank
Download Badge
Engineering Philosophy
Alan Wayne Partin's Degrees
- Doctorate Medicine Johns Hopkins University
- PhD Biomedical Engineering Johns Hopkins University
Why Is Alan Wayne Partin Influential?
(Suggest an Edit or Addition)Alan Wayne Partin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Natural history of progression after PSA elevation following radical prostatectomy. (1999) (2472)
- Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. (1997) (1884)
- Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. (2005) (1258)
- The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. (1993) (1237)
- Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. (1998) (1176)
- Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. (2002) (1072)
- Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. (2001) (1042)
- Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. (2009) (999)
- Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 (2007) (904)
- Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. (2003) (799)
- Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. (1994) (669)
- Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. (2008) (613)
- Predicting 15-year prostate cancer specific mortality after radical prostatectomy. (2011) (600)
- Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. (1997) (596)
- Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. (1990) (594)
- Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. (1996) (577)
- Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. (1993) (574)
- Natural History of Progression After PSA Elevation Following Radical Prostatectomy (1999) (568)
- Germline mutations in HOXB13 and prostate-cancer risk. (2012) (555)
- Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. (1999) (506)
- Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. (2007) (487)
- PCA3: a molecular urine assay for predicting prostate biopsy outcome. (2008) (461)
- A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. (2011) (437)
- Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. (2011) (432)
- A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. (2016) (430)
- A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer (2014) (416)
- The clinical usefulness of prostate specific antigen: update 1994. (1994) (400)
- Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. (1994) (399)
- Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk (2002) (395)
- Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. (2006) (390)
- Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. (2005) (350)
- An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011 (2013) (346)
- Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer (2008) (337)
- Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. (2007) (332)
- Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. (1993) (331)
- Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. (1998) (330)
- Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. (2000) (326)
- PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients (2011) (323)
- Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. (2000) (322)
- Metabolic factors associated with benign prostatic hyperplasia. (2006) (313)
- Comparison of robotic versus human laparoscopic camera control . (1995) (295)
- Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. (2001) (286)
- Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. (2007) (271)
- Cancer as a disease of DNA organization and dynamic cell structure. (1989) (262)
- Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. (1996) (253)
- Characteristics of insignificant clinical T1c prostate tumors (2004) (248)
- Anatomic radical retropubic prostatectomy (2005) (242)
- Can urinary PCA3 supplement PSA in the early detection of prostate cancer? (2014) (234)
- Prognostic Gleason grade grouping: data based on the modified Gleason scoring system (2013) (233)
- OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. (1995) (230)
- The prostate health index selectively identifies clinically significant prostate cancer. (2015) (228)
- The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long‐term follow‐up (2012) (228)
- African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? (2013) (228)
- Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy (2005) (221)
- Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. (2016) (209)
- The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. (2000) (206)
- A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness (2010) (202)
- Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in gleason sum 5 to 7 adenocarcinoma of the prostate (1997) (201)
- Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. (2014) (200)
- Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. (1998) (200)
- Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. (1998) (198)
- Fourier analysis of cell motility: correlation of motility with metastatic potential. (1989) (196)
- Free prostate-specific antigen in serum is becoming more complex. (2002) (195)
- Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. (1996) (188)
- Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. (2017) (185)
- The rat as a model for the study of penile erection. (1989) (183)
- Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. (2009) (182)
- Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. (1991) (179)
- Heredity and prostate cancer: A study of World War II veteran twins (1997) (179)
- Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. (2000) (179)
- Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. (1995) (178)
- Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. (2007) (177)
- 18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer (2015) (176)
- Evidence for two independent prostate cancer risk–associated loci in the HNF1B gene at 17q12 (2008) (174)
- Influence of radical prostatectomy on serum hormone levels. (1998) (171)
- Gleason score 6 adenocarcinoma: should it be labeled as cancer? (2012) (169)
- Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. (1993) (165)
- Correlation of Postoperative Pain to Quality of Recovery in the Immediate Postoperative Period (2005) (164)
- Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. (1989) (163)
- A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. (2018) (160)
- Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. (2010) (156)
- Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. (2010) (155)
- Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer (2018) (154)
- Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. (2000) (153)
- An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. (2004) (148)
- Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. (1999) (147)
- Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. (2000) (144)
- Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy (2005) (144)
- Radical prostatectomy for clinical stage T3a disease (2007) (144)
- Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. (2000) (143)
- Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. (2007) (140)
- Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. (2003) (137)
- Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. (1999) (135)
- Complete robot-assisted laparoscopic urologic surgery: a preliminary report. (1995) (135)
- Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. (2003) (134)
- Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. (2013) (133)
- Telerobotic assisted laparoscopicsurgery: Initial laboratory and clinical experience* (1994) (130)
- Contemporary evaluation of the D'amico risk classification of prostate cancer. (2007) (130)
- Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. (1999) (130)
- alpha1-ADRENOCEPTOR ANTAGONISTS TERAZOSIN AND DOXAZOSIN INDUCE PROSTATE APOPTOSIS WITHOUT AFFECTING CELL PROLIFERATION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (1999) (130)
- SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. (2008) (130)
- Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. (2003) (125)
- Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. (2008) (124)
- Ability of sextant biopsies to predict radical prostatectomy stage. (1998) (123)
- Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. (2003) (121)
- Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease‐free survival among patients with prostate cancer (1992) (120)
- Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4‐216) recognizes nucleophosmin/B23 (1999) (120)
- The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. (1989) (118)
- EPCA-2: a highly specific serum marker for prostate cancer. (2006) (113)
- Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. (2012) (113)
- Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer (2017) (111)
- Comparison of clinical staging algorithms and 111Indium‐capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients (1999) (111)
- Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? (2002) (111)
- Multiparametric magnetic resonance imaging findings in men with low‐risk prostate cancer followed using active surveillance (2013) (108)
- Individual and cumulative effect of prostate cancer risk‐associated variants on clinicopathologic variables in 5,895 prostate cancer patients (2009) (108)
- Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. (2006) (108)
- Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10 (2006) (107)
- Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. (1997) (106)
- Impact of surgical technique (open vs laparoscopic vs robotic‐assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching (2011) (106)
- The use of percent free prostate specific antigen for staging clinically localized prostate cancer. (1998) (105)
- Long-term effects of finasteride on prostate tissue composition. (1999) (104)
- Influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer with established capsular penetration. (1993) (102)
- Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high‐risk cohort of men with negative initial prostate biopsies (2012) (102)
- Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. (2005) (102)
- Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. (2003) (101)
- Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. (2013) (101)
- Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. (1997) (101)
- An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. (1998) (100)
- Clinical utility of indium 111‐capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy (2002) (100)
- Prognostic Value of Preoperative Serum Cell-Free Circulating DNA in Men with Prostate Cancer Undergoing Radical Prostatectomy (2007) (98)
- Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. (2008) (98)
- Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. (1997) (97)
- Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. (2013) (97)
- Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. (2012) (95)
- Trefoil factor 3 overexpression in prostatic carcinoma: Prognostic importance using tissue microarrays (2004) (94)
- Disease progression following radical prostatectomy in men with Gleason score 7 tumor. (1998) (93)
- Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. (2002) (92)
- Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma (2001) (92)
- Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. (1994) (92)
- Identification and characterization of circulating prostate carcinoma cells (2000) (91)
- A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. (1989) (91)
- Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis. (2010) (90)
- Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells (1994) (90)
- Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity (2003) (89)
- PSA markers in prostate cancer detection. (2003) (89)
- Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. (1996) (87)
- Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. (2002) (87)
- Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. (1999) (87)
- Very high risk localized prostate cancer: definition and outcomes (2013) (86)
- Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. (1988) (86)
- Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. (1998) (86)
- The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma (2000) (86)
- Re: “Obesity and hormone‐dependent tumors: cohort and co‐twin control studies based on the Swedish twin registry” (2003) (85)
- Radical prostatectomy for high grade disease: a reevaluation 1994. (1994) (85)
- [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. (2007) (85)
- Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia. (2001) (84)
- Treatment decision‐making for localized prostate cancer: What younger men choose and why (2012) (84)
- Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. (2004) (84)
- Antibody array profiling reveals serum TSP‐1 as a marker to distinguish benign from malignant prostatic disease (2007) (83)
- Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer (1998) (83)
- Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk (2015) (82)
- Obesity and capsular incision at the time of open retropubic radical prostatectomy. (2005) (82)
- Prediction of pathological stage based on clinical stage, serum prostate‐specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era (2017) (82)
- Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer? (2001) (82)
- Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. (1999) (82)
- CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. (2007) (82)
- Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death (2017) (82)
- Impact of surgical margin status on prostate‐cancer‐specific mortality (2012) (81)
- Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. (2003) (81)
- Extended followup of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation. (1996) (81)
- New laparoscopic suturing device: initial clinical experience. (1995) (80)
- Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies (2000) (79)
- Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. (2008) (79)
- Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? (2003) (79)
- Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. (2001) (79)
- Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. (2004) (78)
- Ablation of renal tumors in a rabbit model with interstitial saline-augmented radiofrequency energy: preliminary report of a new technology. (1999) (77)
- A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy. (2000) (77)
- Association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of rat prostatic adenocarcinoma. (1993) (77)
- Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer. (2001) (75)
- Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. (2001) (75)
- The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia (1993) (75)
- The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. (2005) (75)
- Prostate Specific Membrane Antigen Targeted 18F‐DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study (2018) (74)
- Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer (2017) (74)
- Risk score predicts high‐grade prostate cancer in DNA‐methylation positive, histopathologically negative biopsies (2016) (74)
- p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape (2008) (72)
- Prediction of mortality after radical prostatectomy by Charlson comorbidity index. (2010) (72)
- DNA loop domains in mammalian spermatozoa (1989) (72)
- Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. (2001) (71)
- Bioimpedance: Novel use of a minimally invasive technique for cancer localization in the intact prostate (1999) (71)
- Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. (2004) (70)
- Natural history of disease progression in patients who fail to achieve an undetectable prostate‐specific antigen level after undergoing radical prostatectomy (2004) (69)
- Family history facilitates the early diagnosis of prostate carcinoma (1997) (69)
- Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. (1996) (69)
- Association of Prostate Cancer Risk Variants with Clinicopathologic Characteristics of the Disease (2008) (69)
- A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy. (2011) (69)
- Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. (2003) (69)
- Telerobotic assisted laparoscopic surgery: initial laboratory and clinical experience. (1994) (69)
- A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer (2010) (68)
- Extent of extraprostatic extension independently influences biochemical recurrence-free survival: evidence for further pT3 subclassification. (2015) (68)
- Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. (2002) (66)
- Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. (2005) (66)
- Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer (2018) (66)
- Prostate Health Index density improves detection of clinically significant prostate cancer (2017) (65)
- Metastatic potential prediction by a visual grading system of cell motility: prospective validation in the Dunning R-3327 prostatic adenocarcinoma model. (1988) (65)
- Biochemical failure after radical prostatectomy in men with pathologic organ‐confined disease: pT2a versus pT2b (2004) (64)
- Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. (1998) (64)
- Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. (2008) (64)
- Concordance rates for benign prostatic disease among twins suggest hereditary influence. (1994) (64)
- The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. (2008) (63)
- USE OF THE PROSTATE HEALTH INDEX FOR DETECTION OF PROSTATE CANCER: RESULTS FROM A LARGE ACADEMIC PRACTICE (2016) (63)
- Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy. (2012) (63)
- Stronger Association between Obesity and Biochemical Progression after Radical Prostatectomy among Men Treated in the Last 10 Years (2005) (63)
- Erratum: An updated prostate cancer staging nomogram (partin tables) based on cases from 2006 to 2011 (BJU International 111 (22-29)) (2013) (62)
- Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. (2001) (62)
- Endoglin (CD105) as a urinary and serum marker of prostate cancer (2009) (62)
- Increased gene copy number of ERG on chromosome 21 but not TMPRSS2–ERG fusion predicts outcome in prostatic adenocarcinomas (2011) (62)
- The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. (1996) (61)
- Pro–Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer (2009) (61)
- External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. (2008) (61)
- A Double-Blind, Randomized, Neoadjuvant Study of the Tissue Effects of POMx Pills in Men with Prostate Cancer Before Radical Prostatectomy (2013) (61)
- Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations (2008) (61)
- Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. (2013) (61)
- Seminal vesicle invasion by prostate cancer: prognostic significance and therapeutic implications. (2000) (61)
- Initial Experience Performing In-office Ultrasound-guided Transperineal Prostate Biopsy Under Local Anesthesia Using the PrecisionPoint Transperineal Access System. (2018) (61)
- Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. (2009) (60)
- Validation of a biopsy‐based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma (2002) (60)
- The effect of hospital volume on cancer control after radical prostatectomy. (2004) (59)
- Prostate-specific antigen as a marker of disease activity in prostate cancer. (2002) (59)
- Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue. (2004) (59)
- Ability to Predict Metastasis Based On Pathology Findings and Alterations in Nuclear Structure Of Normal-Appearing and Cancer Peripheral Zone Epithelium in the Prostate (2004) (59)
- Evaluation of smooth muscle and collagen subtypes in normal newborns and those with bladder exstrophy. (1996) (58)
- Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. (2002) (58)
- Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. (2010) (58)
- Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. (1996) (58)
- Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up. (2014) (57)
- Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. (1995) (57)
- Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"? (2008) (57)
- Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. I. Testing of a digitization system. (1988) (57)
- Prediction of metastatic potential by a new grading system of cell motility: validation in the Dunning R-3327 prostatic adenocarcinoma model. (1987) (57)
- Comparison of serum PSMA, PSA levels with results of cytogen‐356 ProstaScint® scanning in prostatic cancer patients (1997) (57)
- ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. (2011) (56)
- Validation of the partin nomogram for prostate cancer in a national sample. (2010) (56)
- Campbell-Walsh Urology 10th Edition Review, 10th Edition (2011) (56)
- Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans (2008) (55)
- Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. II. Standardization of methodology for histologic sections. (1988) (55)
- Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. (2004) (54)
- Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology. (2011) (54)
- A quantitative histologic analysis of collagen subtypes: the primary obstructed and refluxing megaureter of childhood. (1998) (54)
- Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. (2000) (53)
- Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume. (1995) (53)
- Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. (2008) (52)
- Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease. (2000) (52)
- Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30‐year experience (2013) (52)
- Variation in IL10 and Other Genes Involved in the Immune Response and in Oxidation and Prostate Cancer Recurrence (2012) (52)
- Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. (1999) (52)
- High prevalence of screen detected prostate cancer in West Africans: implications for racial disparity of prostate cancer. (2014) (51)
- Quantitative nuclear grade (QNG): A new image analysis‐based biomarker of clinically relevant nuclear structure alterations (2000) (50)
- Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. (2007) (50)
- Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. (1994) (50)
- Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia. (1996) (50)
- Pathologic findings in clinical stage A2 prostate cancer. Relation of tumor volume, grade, and location to pathologic stage (1990) (50)
- Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. (1999) (50)
- Effect of DNA methylation on identification of aggressive prostate cancer. (2008) (49)
- Efficacy of continuous local anesthetic infusion for postoperative pain after radical retropubic prostatectomy. (2005) (49)
- PSA levels and the probability of prostate cancer on biopsy (2002) (49)
- Prevalence of BPH and lower urinary tract symptoms in West Africans (2011) (49)
- Correlation of serum prostate specific antigen and quantitative immunohistochemistry. (2000) (47)
- Robotic image-guided needle interventions of the prostate. (2009) (47)
- Telementoring of laparoscopic procedures (1996) (47)
- Predicting the outcome of prostate biopsy: comparison of a novel logistic regression‐based model, the prostate cancer risk calculator, and prostate‐specific antigen level alone (2009) (47)
- Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. (1997) (47)
- T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer (2020) (46)
- Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma. (1999) (46)
- Time lapse videomicroscopic identification of Dunning R-3327 adenocarcinoma and normal rat prostate cells. (1987) (46)
- The relationship between the extent of extraprostatic extension and survival following radical prostatectomy. (2015) (45)
- Contemporaneous comparison of open vs minimally‐invasive radical prostatectomy for high‐risk prostate cancer (2013) (45)
- Clearance rate of serum‐free and total PSA following radical retropubic prostatectomy (1996) (45)
- Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial. (1999) (45)
- Clinical and biological characteristics of familial benign prostatic hyperplasia. (1997) (45)
- A quantitative histological analysis of the dilated ureter of childhood. (1992) (45)
- Obesity and long-term survival after radical prostatectomy. (2014) (45)
- Preoperative characteristics of high‐Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy (2012) (44)
- Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy (2000) (44)
- A neurocomputational model for prostate carcinoma detection (2003) (43)
- Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. (2001) (42)
- Prediction of prognosis in untreated stage A2 prostatic carcinoma (1992) (42)
- Modeling grade progression in an active surveillance study (2014) (42)
- Importance of Reporting the Gleason Score at the Positive Surgical Margin Site: Analysis of 4,082 Consecutive Radical Prostatectomy Cases. (2016) (42)
- Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and Gleason grade with pathological stage at radical prostatectomy. (1992) (42)
- Prostate-specific antigen: what's new in 1997. (1997) (42)
- Comparison of logistic regression and neural net modeling for prediction of prostate cancer pathologic stage. (2002) (42)
- Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate‐risk to very‐high‐risk clinically localised prostate cancer (2019) (41)
- Adhesion formation after transperitoneal nephrectomy: laparoscopic v open approach. (1995) (41)
- Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy (2003) (41)
- Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance. (2013) (41)
- The evolving role of docetaxel in the management of androgen independent prostate cancer. (2003) (41)
- A Phase I Study to Assess the Safety and Cancer‐Homing Ability of Allogeneic Bone Marrow‐Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer (2019) (41)
- Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range. (2002) (41)
- SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. (2016) (41)
- Complications of pelvic lymphadenectomy: do the risks outweigh the benefits? (2010) (41)
- New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. (2017) (40)
- Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. (2017) (40)
- Nuclear shape analysis for assessment of prognosis in renal cell carcinoma. (1990) (40)
- The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. (2013) (40)
- The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. (1998) (40)
- Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. (1997) (39)
- Prediction of patient‐specific risk and percentile cohort risk of pathological stage outcome using continuous prostate‐specific antigen measurement, clinical stage and biopsy Gleason score (2011) (39)
- Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. (2003) (39)
- Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. (2006) (39)
- Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerations. (2004) (38)
- PROSTATE TISSUE COMPOSITION AND RESPONSE TO FINASTERIDE IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (1998) (38)
- Biomarkers for prostate cancer. (2009) (38)
- Concordance Rates and Modifiable Risk Factors for Lower Urinary Tract Symptoms in Twins (2006) (37)
- Automated image analysis system for detecting boundaries of live prostate cancer cells. (1998) (36)
- Progression after radical prostatectomy for men in their thirties compared to older men (2008) (36)
- Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. (2006) (36)
- Management of high-risk populations with locally advanced prostate cancer. (2003) (36)
- Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. (2003) (36)
- Minilaparotomy radical retropubic prostatectomy: technique and results. (1998) (36)
- Adenocarcinoma of the prostate in men younger than 40 years of age: diagnosis and treatment with emphasis on radical prostatectomy findings. (1999) (36)
- Campbell- Walsh urology ninth edition review (2013) (36)
- The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. (1990) (35)
- International surgical telementoring: our initial experience. (1998) (35)
- Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. (2001) (35)
- Small Integrin-Binding Proteins as Serum Markers for Prostate Cancer Detection (2009) (35)
- Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening. (2002) (35)
- Long‐Term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis (2008) (35)
- Prostatic growth rate determined from MRI data: age-related longitudinal changes. (1999) (35)
- Differential nuclear matrix protein expression in prostate cancers: correlation with pathologic stage. (1998) (34)
- Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. (2009) (34)
- Detection of intact prostate cancer cells in the blood of men with prostate cancer. (1997) (34)
- Multicenter comparison of the diagnostic performance of free prostate-specific antigen. (1996) (34)
- Adjuvant radiation with androgen‐deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit (2019) (33)
- Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. (2002) (33)
- Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6–4.0 ng/mL range of total PSA (2004) (33)
- Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. (2002) (33)
- Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. (2000) (32)
- Prediction of prostate carcinoma stage by quantitative biopsy pathology (2001) (32)
- The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma. (1993) (32)
- Review of the literature: PCA3 for prostate cancer risk assessment and prognostication. (2011) (31)
- Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer. (2012) (31)
- Incidental non-Hodgkin's lymphoma in patients with localized prostate cancer. (1999) (31)
- Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint (2007) (31)
- Quantitative biopsy pathology for the prediction of pathologically organ‐confined prostate carcinoma (2003) (31)
- The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer. (1996) (31)
- Serum leptin and pathological findings at the time of radical prostatectomy. (2005) (31)
- Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. (1994) (30)
- Partin tables: past and present (2003) (30)
- Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge. (2002) (30)
- Can aggressive prostatic carcinomas be identified and can their natural history be altered by treatment? (1995) (30)
- Prediction of metastatic potential in an animal model of prostate cancer: flow cytometric quantification of cell surface charge. (1989) (30)
- Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy. (2008) (30)
- A quantitative histological evaluation of the dilated ureter of childhood. II: Ectopia, posterior urethral valves and the prune belly syndrome. (1995) (30)
- Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols (2015) (29)
- Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians (2010) (29)
- Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. (2006) (29)
- Allogeneic versus autologous blood transfusion and survival after radical prostatectomy (CME) (2014) (29)
- Measurement of urinary N-acetyl-β-D-glucosaminidase to assess renal ischemia during laparoscopic operations (1999) (29)
- Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients (2017) (29)
- Retropubic and Suprapubic Open Prostatectomy (2012) (29)
- Spinal Anesthesia Does Not Impact Prostate Cancer Recurrence in a Cohort of Men Undergoing Radical Prostatectomy: An Observational Study (2014) (29)
- Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins. (1997) (29)
- Nuclear morphometry accurately predicts recurrence in clinically localized renal cell carcinoma. (1993) (28)
- Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications. (2001) (28)
- Relationship between changes in prostate-specific antigen and prognosis of prostate cancer. (1993) (28)
- Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. (2007) (28)
- The problem of cutoff levels in a screened population (2001) (28)
- Causes of death after radical prostatectomy at a large tertiary center. (2011) (28)
- Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. (2005) (28)
- Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death (2021) (28)
- Updating risk prediction tools: A case study in prostate cancer (2012) (28)
- Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy: Reply by authors (1998) (28)
- Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow‐up after radical prostatectomy (2010) (27)
- Prognostic value of Her‐2/neu and DNA index for progression, metastasis and prostate cancer‐specific death in men with long‐term follow‐up after radical prostatectomy (2008) (27)
- Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. (2002) (27)
- The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer. (2007) (26)
- Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent (2008) (26)
- The clinical usefulness of percent free-PSA. (1996) (26)
- The significance of a positive bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted. (2010) (26)
- Impact of robotic technique and surgical volume on the cost of radical prostatectomy. (2013) (26)
- The importance of pelvic lymph node dissection in men with clinically localized prostate cancer. (2006) (25)
- Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. (2016) (25)
- Prediction of Prostate-Specific Antigen Recurrence in Men with Long-term Follow-up Postprostatectomy Using Quantitative Nuclear Morphometry (2008) (25)
- Identification of men with the highest risk of early disease recurrence after radical prostatectomy (2014) (25)
- Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis (2007) (24)
- Obesity and prostate enlargement in men with localized prostate cancer (2011) (24)
- SELDI protein profiling of dunning R‐3327 derived cell lines: Identification of molecular markers of prostate cancer progression (2007) (24)
- Histopathologic characterization of hereditary benign prostatic hyperplasia. (1996) (24)
- Urinary Biomarkers for Prostate Cancer. (2016) (24)
- Treatment decision-making for localized prostate cancer: what younger men choose and why (2011) (24)
- Prostate-specific antigen: update 2006. (2006) (23)
- Comprar Campbell-Walsh Urology. 4 Vol., 10th Edition | Craig A. Peters | 9781416069119 | Saunders (2011) (23)
- Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy. (2011) (23)
- Standardization of two immunoassays for human glandular kallikrein 2. (2003) (22)
- Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism. (2002) (22)
- Elevated prostate-specific antigen, abnormal prostate evaluation on digital rectal examination, and transrectal ultrasound and prostate biopsy. (1998) (21)
- Radical prostatectomy in men less than 50 years old. (1995) (21)
- Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. (2001) (21)
- Treatment of early stage prostate cancer: radical prostatectomy. (1994) (21)
- Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? (2007) (21)
- Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. (2002) (21)
- Mass Spectroscopy as a Discovery Tool for Identifying Serum Markers for Prostate Cancer (2001) (21)
- Radical Retropubic and Perineal Prostatectomy (2012) (21)
- Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia results at three months through four years. (2004) (21)
- Campbell Walsh Wein Urology (2021) (21)
- Expectant management of localized prostate cancer. (2003) (20)
- Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program (2010) (20)
- Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy (2017) (20)
- Prostate Health Index (PHI) Predicts High-stage Pathology in African American Men. (2016) (19)
- Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. (2009) (19)
- In vivo measurement of tumor conductiveness with the magnetic bioimpedance method (2000) (19)
- Current Clinical Applications of the In-capromab Pendetide Scan (ProstaScint(R) Scan, Cyt-356). (2001) (19)
- Prostate Cancer Tumor Markers (2012) (19)
- AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy (2012) (18)
- Anatomic approach for placement of surgical drains after radical retropubic prostatectomy: long-term effects on postoperative pain. (1996) (18)
- Evolution of the clinical presentation of men undergoing radical prostatectomy for high‐risk prostate cancer (2012) (18)
- Clinical evaluation of a novel method for the measurement of prostate‐specific antigen, AccuPSATM, as a predictor of 5‐year biochemical recurrence‐free survival after radical prostatectomy: results of a pilot study (2012) (18)
- Nuclear shape analysis for the assessment of local invasion and metastases in clinically localized prostate carcinoma (1994) (18)
- Is clinical stage T2c prostate cancer an intermediate‐ or high‐risk disease? (2015) (18)
- Prediction of locoregional extension and metastatic disease in prostate cancer: a review (2000) (18)
- Outcomes of men with an elevated prostate‐specific antigen (PSA) level as their sole preoperative intermediate‐ or high‐risk feature (2014) (18)
- A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer (2011) (17)
- PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. (2019) (17)
- Indicators of pathologic stage of prostate cancer and their use in clinical practice. (2001) (17)
- Serum prostate‐specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density (2014) (17)
- Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. (2020) (17)
- Quantitative Grading of Tissue and Nuclei in Prostate Cancer for Prognosis Prediction (1997) (16)
- The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-up. (2009) (16)
- Urinary glycoproteins associated with aggressive prostate cancer (2020) (16)
- Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. (2011) (16)
- Surgical margin status after radical retropubic prostatectomy (2005) (16)
- Influence of sextant prostate needle biopsy or surgery on the detection and harvest of intact circulating prostate cancer cells. (1999) (16)
- Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia. (1995) (16)
- Advances in the selection of patients with prostate cancer for active surveillance (2021) (16)
- Vasectomy and prostate cancer. (2004) (15)
- Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men. (2002) (15)
- Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer (2005) (15)
- DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction. (2009) (15)
- Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI). (2003) (15)
- Nomograms for clinically localized prostate cancer. Part I: radical prostatectomy. (2002) (15)
- Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy? (2016) (15)
- The use of nuclear morphometry to predict response to therapy in Wilms' tumor (1992) (15)
- Effect of intra‐observer variation in prostate volume measurement on prostate‐specific antigen density calculations among prostate cancer active surveillance participants (2011) (15)
- Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy (2018) (14)
- Correlation of prognosis to nuclear roundness and to flow cytometric light scatter. (1987) (14)
- Nuclear morphometry predicts disease‐free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy (1999) (14)
- Diagnosis of localized prostate cancer: 10 years of progress (2000) (14)
- An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. (2016) (14)
- DNA content in the diagnostic biopsy for benign‐adjacent and cancer‐tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme (2010) (14)
- Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis. (2013) (14)
- Ureteral bladder augmentation using the lower pole ureter of a duplicated system. (1996) (14)
- Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer (2019) (14)
- Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance (2020) (13)
- Nuclear morphometry as a predictor of response to therapy in Wilms tumor: a preliminary report. (1990) (13)
- Exploratory data analysis groupware for qualitative and quantitative electrophoretic gel analysis over the Internet‐WebGel (1999) (13)
- Complexed prostate‐specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy (2007) (13)
- The impact of preoperative erectile dysfunction on survival after radical prostatectomy (2010) (13)
- Management of patients with an increasing prostate-specific antigen after radical prostatectomy (2004) (13)
- Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen? (2002) (13)
- Role of laparoscopy in the diagnosis and treatment of prostate cancer. (1996) (13)
- Benign and malignant prostatic neoplasms: human studies. (1994) (13)
- The use of nuclear morphometry to predict prognosis in pediatric urologic malignancies: a review. (1993) (12)
- Report on Prostate Cancer Tumor Marker Workshop 1999 (2000) (12)
- Hereditary and familial prostate cancer: biologic aggressiveness and recurrence. (2000) (12)
- Management of patients with an increasing prostate-specific antigen after radical prostatectomy (2004) (12)
- Applying complexed prostate-specific antigen to clinical practice. (2004) (12)
- The development of a system for the quantitative analysis of tumor cell motility: Application to prostate cancer (1990) (12)
- Implementation of a Surgeon‐Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy (2017) (12)
- Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancer. (2006) (11)
- Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. (2003) (11)
- The role of free prostate-specific antigen in prostate cancer detection (2000) (11)
- Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series (2017) (11)
- The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality (2017) (11)
- Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay. (1999) (11)
- Trends in immediate perioperative morbidity and delay in discharge after open and minimally invasive radical prostatectomy (RP): a 20‐year institutional experience (2013) (11)
- Nuclear morphometry and prognosis in favorable histology Wilms' tumor: A prospective reevaluation. (1999) (11)
- Progress toward identifying aggressive prostate cancer. (2004) (11)
- Prostate-specific antigen after anatomic radical retropubic prostatectomy : Patterns of recurrence and cancer control : Prostate-specific antigen: the best prostatic tumor marker (1997) (11)
- Prediction of disease-free survival after therapy in Wilms' tumor using nuclear morphometric techniques. (1994) (11)
- Transurethral radiofrequency therapy for benign prostatic hyperplasia using a novel saline-liquid conductor: the virtual electrode. (2000) (11)
- Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance. (2020) (11)
- Significance of preoperative PSA velocity in men with low serum PSA and normal DRE (2010) (10)
- Predicting the risk of non-organ-confined prostate cancer when perineural invasion is found on biopsy. (2014) (10)
- Feasibility of Integrating Canine Olfaction with Chemical and Microbial Profiling of Urine to Detect Lethal Prostate Cancer (2020) (10)
- Retracted: Analysis of a serum test for prostate cancer that detects a second epitope of EPCA‐2 (2009) (10)
- High-grade prostatic adenocarcinoma present in a single biopsy core is associated with increased extraprostatic extension, seminal vesicle invasion, and positive surgical margins at prostatectomy. (2012) (10)
- Campbell-Walsh Urology. 4 Vol., 10th Edition (2011) (10)
- Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy (2016) (10)
- Should the diagnosis of benign prostatic hyperplasia be made on prostate needle biopsy? (2002) (10)
- Frequent occurrence of metastatic disease in patients with renal cell carcinoma and intrahepatic or supradiaphragmatic intracaval extension treated with surgery: an outcome analysis. (1998) (10)
- Urinary incontinence after radical retropubic prostatectomy. (1999) (10)
- Comprar Campbell-Walsh Urology 10th Edition Review, 10th Edition | Alan J. Wein | 9781437723939 | Saunders (2011) (10)
- Reply to Juan Morote’s Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Eur Urol 2009;56:659–68 (2010) (10)
- Prostate cancer early detection clinical practice guidelines in oncology. (2003) (10)
- THE USE OF % FREE PSA (%fPSA) TO PREDICT PROSTATE CANCER PROBABILITIES: AN ELEVEN CENTER PROSPECTIVE STUDY USING AN AUTOMATED IMMUNOASSAY SYSTEM IN A POPULATION WITH NON-SUSPICIOUS DRE (1999) (10)
- Cyr61 is regulated by cAMP‐dependent protein kinase with serum levels correlating with prostate cancer aggressiveness (2012) (10)
- Clinical interpretation of prostate biopsy reports. (2006) (10)
- Minilaparotomy radical retropubic prostatectomy: updated technique and results. (2000) (10)
- Evaluation of two mitochondrial DNA biomarkers for prostate cancer detection. (2015) (9)
- Campbell-Walsh Urology: 4-Volume Set (11th Ed.) (2016) (9)
- PROSTATIC GROWTH RATE DETERMINED FROM MRI DATA: AGE RELATED LONGITUDINAL CHANGES (1999) (9)
- Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy (2013) (9)
- Prostate cancer and chemotherapy. (2004) (9)
- Cell motility as an index of metastatic ability in prostate cancers: results with an animal model and with human cancer cells. (1992) (9)
- ARTIFICIAL INTELLIGENCE SYSTEM IN PREDICTION OF LYMPH NODE INVOLVEMENT IN RADICAL PROSTATECTOMY PATIENTS (1999) (8)
- Tissue microarrays in prostate cancer research. (2004) (8)
- Repeat prostate biopsies predict location of index cancer in an active surveillance cohort (2011) (8)
- The significance of perineural invasion found on needle biopsy of the prostate: implications for definitive therapy. (2000) (8)
- Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP). (2017) (8)
- Nuclear morphometry as a prognostic indicator for genitourinary rhabdomyosarcoma: a preliminary investigation. (1990) (8)
- The use of percent free PSA for early detection of prostate cancer. (1999) (8)
- Prostate cancer--educating ourselves and our nonurological colleagues. (1996) (8)
- Prostate cancer: detection, staging, and treatment of localized disease. (1999) (8)
- High-grade prostatic intraepithelial neoplasia on a prostate biopsy-what does it mean? (2002) (8)
- What does prostate-specific antigen recurrence mean? (2000) (8)
- Kinetics of tumor growth of prostate carcinoma estimated using prostate-specific antigen. (2005) (7)
- Retraction: analysis of a serum test for prostate cancer that detects a second epitope of EPCA‐2 (2012) (7)
- 1344: Metabolic Factors Associated with Benign Prostatic Hyperplasia: The Baltimore Longitudinal Study of Aging (2006) (7)
- Detecting Prostate Cancer with Molecular Markers: uPM3. (2005) (7)
- Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer. (2021) (7)
- Needle Biopsy of Recurrent Adenocarcinoma of the Prostate After Radical Prostatectomy (2000) (7)
- Finasteride and prostate cancer. (2004) (7)
- Re: "Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish twin registry". (2006) (7)
- Original Articles: Prostate Cancer (1995) (7)
- Risk Factors for Intraprostatic Incision into Malignant Glands at Radical Prostatectomy. (2015) (7)
- Development of Parallel Reaction Monitoring Assays for the Detection of Aggressive Prostate Cancer Using Urinary Glycoproteins. (2021) (7)
- MP46-09 INDICATIONS FOR INTERVENTION DURING ACTIVE SURVEILLANCE OF PROSTATE CANCER: A COMPARISON OF THE JOHNS HOPKINS AND PRIAS PROTOCOLS (2014) (7)
- Bisphosphonates in metastatic prostate cancer. (2003) (7)
- 1847 [-2]PROPSA IN COMBINATION WITH PSA AND FREE-PSA, USING THE BECKMAN COULTER ACCESS IMMUNOASSAY SYSTEMS IMPROVES PROSTATE CANCER DETECTION RELATIVE TO PSA AND FREE PSA. A MULTI-CENTER PROSPECTIVE CLINICAL STUDY (2010) (7)
- DETECTION OF PROSTATE CANCER WITH %FPSA AND HK2 WHEN PSA IS 2-4 NG/ML (1999) (7)
- Treatment methods for early and advanced prostate cancer (2008) (7)
- Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease. (2004) (6)
- Neural network based systems for prostate cancer stage prediction (2000) (6)
- Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents. (2001) (6)
- Prostate-specific antigen in men born with bladder exstrophy. (1997) (6)
- 1451: Prostate Specific Antigen Doubling Time after Radical Prostatectomy as a Predictor of Cause Specific Survival (2004) (6)
- Tumor markers: an update on human kallikrein 2. (2000) (6)
- NCCN practice guidelines for early detection of prostate cancer (1999) (6)
- In Reply: Re: The Clinical Usefulness of Prostate Specific Antigen: Update 1994 (1996) (6)
- Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer (2011) (6)
- 1623: Biological Variation of PCA3 Score in Men Previously Diagnosed with Prostate Cancer (2007) (6)
- Predicting the long-term risk of prostate cancer-specific mortality after radical prostatectomy. (2009) (6)
- The biology of prostate cancer: new and future directions in predicting tumor behavior. (1992) (6)
- Prostate Cancer, 2nd International consultation on Prostate Cancer (2000) (6)
- Quantitative Nuclear Grade (2005) (5)
- Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy. (2013) (5)
- Docetaxel in androgen‐independent prostate cancer: an update (2004) (5)
- Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation (2017) (5)
- [-2]proPSA for Prostate Cancer Detection: an NCI Early Detection Research Network Validation Study (2009) (5)
- COMPLEXED PROSTATE SPECIFIC ANTIGEN (cPSA): RESULTS OF A MULTICENTER BIOPSY EXPERIENCE (1999) (5)
- PCA3 Urinary Biomarker for Prostate Cancer. (2010) (5)
- Prostate specific antigen doubling time (PSADT) predicts for distant failure and prostate cancer specific survival (PCSS) in men with biochemical relapse after radical prostatectomy (RP). (2004) (5)
- Neural network prediction of prostate tissue composition based on magnetic resonance imaging analysis. A pilot study. (2000) (5)
- Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) (2005) (5)
- The role of prostate needle biopsy in evaluation of chemopreventive agents. (2001) (5)
- Early detection of prostate cancer continues to support rational, limited screening. (2013) (5)
- Clinical evaluation of the Elecsys total prostate-specific antigen assay on the Elecsys 1010 and 2010 systems. (2002) (5)
- Comparison of nuclear shape in aspirated and histologic specimens of prostatic carcinoma. (1992) (5)
- The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate. (2002) (5)
- Managing the complications of advanced prostate cancer (2008) (5)
- Obesity and prostate cancer detection and progression. (2004) (4)
- Endothelin-a receptor antagonists and advanced prostate cancer. (2004) (4)
- 1431: Further Analysis of Serum Based EPCA-2 as a Specific Prostate Cancer Associated Biomarker (2007) (4)
- Patterns of Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy for Low-risk Men. (2017) (4)
- Contemporary Assessment of the Most Cited Clinical, Basic Science, and Guidelines Papers in Urology: A Reference for Urology Journal Club. (2020) (4)
- A randomized, placebo-controlled trial of celecoxib in men prior to receiving prostatectomy for clinically localized adenocarcinoma of the prostate: Evaluation of drug-specific biomarker modulation (2007) (4)
- Does sextant prostate biopsy provide adequate sampling for early detection of prostate cancer? (2000) (4)
- LONG-TERM SURVIVAL AFTER RADICAL PROSTATECTOMY FOR MEN WITH HIGH PATHOLOGIC GLEASON SUM (2009) (4)
- Genetic tests for prostate cancer. (2013) (4)
- ANALYSIS OF A SECOND EPCA-2 EPITOPE AS A SERUM TEST FOR PROSTATE CANCER (2008) (4)
- VALIDATION OF THE PARTIN TABLES FOR PREDICTING PATHOLOGIC STAGE OF CLINICALLY CONFINED PROSTATE CANCER (1999) (4)
- Complications after open and robot‐assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial (2020) (4)
- CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS. (2016) (4)
- Comparison of Biochemical Recurrence–Free Survival Between Periprostatic and Pelvic Lymph Node Metastases of Prostate Cancer (2013) (4)
- Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium (2021) (4)
- Role of biobanking in urology: a review (2016) (4)
- 2151 ASSOCIATION OF PROSTATE CANCER RISK SNPS WITH AGE AT TREATMENT: POTENTIAL FOR PREDICTION OF EARLY ONSET OF DISEASE (2010) (4)
- Anatomic Radical Retropubic Prostatectomy for Prostate Cancer (2001) (4)
- An experimental strategy for quantitative analysis of the humoral immune response to prostate cancer antigens using natural protein microarrays (2007) (3)
- 744: Cancer Control Following Radical Prostatectomy in Men with Capsular Incision (2007) (3)
- Predicting cancer on repeat biopsy: Results of a multicenter prospective evaluation of complexed PSA (2003) (3)
- Long Term-Survival after Radical Prostatectomy for men with High Gleason Sum. (2010) (3)
- Vitamin d for the management of prostate cancer. (2004) (3)
- A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance (2021) (3)
- Histological Changes in Benign Prostate Biopsies Following Long-Term Finasteride Therapy for Prostatic Hyperplasia (1999) (3)
- Is Prostate-Specific Antigen Surveillance Necessary in Men with Benign Prostate Pathology following Radical Cystoprostatectomy for Bladder Cancer? (2010) (3)
- Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American men. (2003) (3)
- Commentary of "Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer (2011) (3)
- Randomized trials of prostate cancer screening. (2009) (3)
- 1188: Time to PSA Recurrence after Radical Prostatectomy and Risk of Prostate Cancer Specific Mortality (2006) (3)
- Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostate. (2013) (3)
- CANCER DETECTION RATE FOR PATIENTS WITH TOTAL PSA CONCENTRATIONS <4 NG/ML: COMPARISON OF TOTAL, FREE, AND COMPLEXED PSA (1999) (3)
- Predicting Pathological Stage of Localized Prostate Cancer-Reply (1997) (3)
- 570: Preoperative Serum GSTP1 CPG Island Hypermethylation Predicts the Risk of Early PSA Recurrence Following Radical Prostatectomy (2005) (3)
- Single nucleotide polymorphisms and prostate cancer susceptibility. (2008) (3)
- PII-LBA2 VALIDATION OF A NOVEL NON-INVASIVE URINE EXOSOME GENE EXPRESSION ASSAY TO PREDICT HIGH-GRADE PROSTATE CANCER IN PATIENTS UNDERGOING INITIAL BIOPSY WITH AN EQUIVOCAL PSA. (2015) (3)
- 327: Updated Recurrence-Free Survival (RFS) Prediction Model Following Radical Prostatectomy (RRP) (2007) (3)
- 1135: Who Dies from Prostate Cancer after Radical Prostatectomy? Influence of Post-Operative Prostate Specific Antigen Doubling Time, Pathological Gleason Sum, and Time from Surgery to Biochemical Recurrence (2005) (3)
- Perspectives in Cancer Research Cancer as a Disease of DNA Organization and Dynamic Cell Structure1 (1989) (3)
- IMPACT OF SALVAGE ANDROGEN DEPRIVATION THERAPY ON OVERALL SURVIVAL IN MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY (2009) (3)
- Conflicting insights into the role of watchful waiting in the management of adenocarcinoma of the prostate. (2006) (3)
- Cell Motility and Structural Harmonics in Prostate Cancer (1991) (3)
- 1874: External Validation of the Prostate Cancer Risk Calculator (2007) (3)
- 1875: Comparison between the Prostate Cancer Risk Calculator and Serum PSA (2007) (3)
- Long-Term Survival after Radical Prostatectomy for men with High Gleason Sum in the Pathological Specimen (2010) (3)
- 1465 OUTCOMES OF MEN WITH AN ELEVATED PSA AS THEIR SOLE PREOPERATIVE INTERMEDIATE OR HIGH RISK FEATURE (2011) (3)
- MOLECULAR STAGING OF MEN WITH SEMINAL VESICLE INVASION AND NEGATIVE LYMPH NODES AT RADICAL PROSTATECTOMY (1999) (3)
- Risk factors for metastatic prostate cancer: A sentinel event case series (2017) (2)
- Best of the 2017 AUA Annual Meeting: Highlights From the 2017 American Urological Association Annual Meeting, May 12-16, 2017, Boston, MA. (2017) (2)
- Risk assessment for high-grade prostate cancer using a novel cancer-specific biomarker assay derived from autoantibody signatures (2017) (2)
- 1530: Results of A Multi-Center Trial of A New Generation Cooled Tumt for BPH (2004) (2)
- Electromagnetic holographic imaging of bioimpedance (1998) (2)
- Nuclear morphology of prostatic carcinoma: comparison of computerized image analysis (CAS 200) versus video planimetry (DynaCELL). (1991) (2)
- Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer (2022) (2)
- Prediction of Metastatic Potential by a New Grading System of Cell Motility: Validation in the Dunning R-3327 Rat Prostatic Adenocarcinoma Model and Preliminary Application to Human Urological Cancer (1987) (2)
- New approaches to the evaluation of the metastatic ability of renal cancer and new approaches to chemotherapy. (1990) (2)
- Robotic prostatectomy diffusion safety concerns: reality or just illusion? (2014) (2)
- Evolving Role of Pro-PSA as a New Serum Marker for the Early Detection of Prostate Cancer. (2002) (2)
- Dawning of the age of chemotherapy for prostate cancer. (2005) (2)
- Natural History of Pathologically Organ-Confined (pT2), Gleason ≤ 6 Prostate Cancer Following Radical Prostatectomy (2008) (2)
- Total, Complexed, and Free PSA Forms and Human Glandular Kallikrein 2 (2004) (2)
- Know your nomograms (2014) (2)
- MP35-08 INCORPORATING PROSTATE HEALTH INDEX DENSITY, MRI, AND PRIOR NEGATIVE BIOPSY STATUS TO IMPROVE THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER (2018) (2)
- 1553: Intermediate Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH (2005) (2)
- DIGITAL RECTAL EXAMINATION AND IMAGING STUDIES ARE UNNECESSARY IN MEN WITH AN UNDETECTABLE PSA FOLLOWING RADICAL PROSTATECTOMY (1999) (2)
- PSA doubling time (PSADT) and proximal PSA value predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP). (2017) (2)
- Nuclear morphometric analysis of metastasis in Wilms' tumor after multimodal therapy: comparison with primary tumor. (1995) (2)
- Results of a multicenter prospective evaluation of complexed PSA (2002) (2)
- 1582: Who is Cured? How Long after Radical Prostatectomy Can PSA Rise? (2006) (2)
- Radical surgery for renal-cell carcinoma: caval neoplastic excision, adrenalectomy, lymphadenectomy, adjacent organ resection (2004) (2)
- PD50-04 UTILITY OF MULTIPARAMETRIC MRI IN THE RISK STRATIFICATION OF MEN WITH GRADE GROUP 1 PROSTATE CANCER ON ACTIVE SURVEILLANCE (2019) (2)
- Abstract 2236: Nuclear roundness variance predicts prostate cancer progression, metastasis and death: A prospective evaluation with up to 25 years of follow-up after radical prostatectomy (2010) (2)
- PROSTATE TISSUE EFFECTS OF SAW PALMETTO EXTRACT IN MEN WITH SYMPTOMATIC BPH (1999) (2)
- Early hormonal therapy for prostate cancer: the good, the bad, and the ugly. (2005) (2)
- 2055 PROSTATE HEALTH INDEX (PHI) FOR REDUCING OVERDETECTION OF INDOLENT PROSTATE CANCER AND UNNECESSARY BIOPSY WHILE IMPROVING DETECTION OF AGGRESSIVE CANCERS (2013) (2)
- Mortality Following Prostate Cancer Recurrence After Radical Prostectomy—Reply (2005) (2)
- Angiotensin receptor autoantibodies as exposures that modify disease progression: Cross sectional, longitudinal and in vitro studies of prostate cancer (2019) (2)
- Prostatitis syndromes and benign prostatic hyperplasia. (1999) (2)
- Incidence of neuroendocrine cells in the seminal vesicles and the prostate – an immunohistochemical study (2004) (2)
- Tissue-based genomics to augment post-prostatectomy risk stratification in a natural history cohort. (2015) (2)
- 691: Effects of Testosterone Administration on Prostate Tissues in Men with Adam Syndrome (2006) (2)
- 551 Validation of biopsy-based pathological algorithm to predict lymph node metastases in clinically localized prostate cancer (PCA): impact on changing treatment modalities (2004) (2)
- Chemoprevention and prostate cancer. (2003) (2)
- 726: Death in Patients with Recurrent Prostate Cancer after Radical Prostatectomy: PSADT Subgroups and Their Associated Contributions to All-Cause Mortality (2007) (1)
- Association of variants at two 17q loci with prostate cancer risk in European and African Americans (2011) (1)
- Validation of the Decipher prostate cancer classifier in intermediate to high-risk men treated with radical prostatectomy but without additional therapy upon PSA rise. (2015) (1)
- COMMENT ON: DISEASE PROGRESSION FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH GLEASON SCORE 7 TUMOR. AUTHORS' REPLY (1999) (1)
- Definitive therapy for men with newly-diagnosed oligometastatic prostate cancer: Initial surgical outcomes from a phase II study (2018) (1)
- PD40-09 EVALUATING THE IMPACT OF LENGTH OF TIME FROM DIAGNOSIS TO SURGERY IN PATIENTS WITH UNFAVORABLE INTERMEDIATE TO VERY HIGH-RISK CLINICALLY LOCALIZED PROSTATE CANCER (2019) (1)
- CHEK2 MUTATIONS INCREASE RISK FOR PROSTATE CANCER BUT DO NOT DIFFERENTIATE RISK OF LETHAL FROM INDOLENT DISEASE: PD37‐11 (2017) (1)
- Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer. (2023) (1)
- Utilisation of percent free PSA in the total PSA (TPSA) range 2–4 NG/ML does not substantially increase the number of biopsies needed to find significant prostate cancer (2003) (1)
- Androgens and the androgen receptor in normal prostate (2005) (1)
- 995 ALLOGENEIC BLOOD TRANSFUSION IS AN INDEPENDENT PREDICTOR OF OVERALL SURVIVAL AFTER RADICAL PROSTATECTOMY (2013) (1)
- Comprar Treatment Methods for Early and Advanced Prostate Cancer | Roger S. Kirby | 9780415458931 | Informa Healthcare (2008) (1)
- 332: Updated Nomogram to Predict Pathologic stage of Prostate Cancer Given PSA, Clinical stage, and Biopsy Gleason Score (Partin Tables) Based on Cases From 2000-2005 (2007) (1)
- 384: Prognostic Significance of Gleason Grade Discrepancies between Needle Biopsy and Radical Prostatectomy (2007) (1)
- Hugh Hampton Young, benign prostatic hyperplasia, and "the cure of prostatic obstruction". (2005) (1)
- 1589: Adjuvant Weekly Docetaxel for High-Risk Prostate Cancer Patients After Radical Prostatectomy (2005) (1)
- Best of the 2018 AUA Annual Meeting. (2018) (1)
- PD46-09 RISK STRATIFICATION OF AGGRESSIVE PROSTATE CANCER BASED ON COMBINED EPIGENETIC AND CLINICAL DATA OF MEN WITH INITIAL CANCER-NEGATIVE BIOPSIES (2015) (1)
- chapter 98 Prostate Cancer Tumor Markers (2012) (1)
- Risk factors for metastatic prostate cancer: A sentinel event case series. (2017) (1)
- Weighing the risks: prostate cancer versus cardiovascular disease. (2008) (1)
- 725: Radical Prostatectomy for Clinical Stage T3 Disease (2007) (1)
- MP46-06 SELECTION CRITERIA FOR EARLY BIOCHEMICAL RECURRENCE IN A HIGH-RISK RADICAL PROSTATECTOMY COHORT (2014) (1)
- Public health impact of PSA doubling time after radical prostatectomy on prostate cancer specific and overall survival. (2006) (1)
- Letter-from-the-Editor for the January 2006 issue of UROLOGY (2006) (1)
- A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization (2020) (1)
- MP40-10 EXTENDED VALIDATION RESULTS FROM A PROSPECTIVE ADAPTIVE UTILITY TRIAL CONFIRM PERFORMANCE OF A NOVEL URINE EXOSOME GENE EXPRESSION ASSAY TO PREDICT HIGH-GRADE PROSTATE CANCER AT INITIAL BIOPSY (2018) (1)
- Nuclear structure by semi-automated Iiage analysis classifies prostate cancer feulgen-stained nuclei captured from gleason graded tissue patterns. (2006) (1)
- Does laterality of positive needle biopsy in clinical T2a patients with prostate cancer affect biochemical recurrence-free survival? (2008) (1)
- 1632 EFFECT OF INTRA-OBSERVER VARIATION IN PROSTATE VOLUME CALCULATIONS IN PROSTATE CANCER ACTIVE SURVEILLANCE GROUP (2011) (1)
- 818PPSA doubling time (PSADT) and proximal PSA predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP): Implications for patient counseling and clinical trial design (2017) (1)
- 982 EVALUATION OF THE PROSTATE HEALTH INDEX (PHI)1 IN THE 2 TO 4, AND 4 TO 10 NG/ML PSA RANGES: RESULTS FROM A MULTI-SITE, PROSPECTIVE, CLINICAL EVALUATION (2011) (1)
- EVALUATION OF PSA FOR EARLY DETECTION OF PROSTATIC CANCER IN MEN (2003) (1)
- Risk-AssociatedVariants onClinicopathologic Variables in 5 , 895 ProstateCancer Patients (2009) (1)
- THE PROBABILITY OF HAVING PROSTATE CANCER GIVEN AGE, SERUM PSA, AND DRE AS DETERMINED FROM THE TYROL SCREENING PROJECT (1999) (1)
- SIGNIFICANCE OF PREOPERATIVE PSA VELOCITY (PSAV) IN MEN WITH LOW SERUM PSA AND NORMAL DRE (2008) (1)
- PROSTATE CANCER-SPECIFIC SURVIVAL FOLLOWING SALVAGE RADIOTHERAPY VS. OBSERVATION IN MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY (2008) (1)
- Where it all Began. (2017) (1)
- Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. (2009) (1)
- POD-05.08: Predicting the Long-Term Risk of Prostate Cancer-Specific Mortality After Radical Prostatectomy (2009) (1)
- Translation research in prostate cancer. (2006) (1)
- 54-year-old male with high-grade prostatic intraepithelial neoplasia on prostate biopsy. (2003) (1)
- Prostate Cancer: Epidemiology & Natural History IIIMP78-19 RACIAL DISPARITIES IN ONCOLOGIC OUTCOMES AFTER RADICAL PROSTATECTOMY: LONG-TERM FOLLOW-UP (2014) (1)
- Do Racial Differences In Prostate Size Explain Higher Serum PSA Concentrations Among Black Men? (2012) (1)
- Imaging , Diagnosis , Prognosis PTEN Protein Loss by Immunostaining : Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients (2011) (1)
- 1265: International Multi-Center Comparison of Complexed Prostate Specific Antigen (CPSA) with Total PSA, Percent CPSA, and Percent free PSA (2004) (1)
- Randomized trials of selenium, vitamin e, or vitamin C for prostate cancer prevention. (2009) (1)
- POD-02.10: Individual and Cumulative Effect of Prostate Cancer Risk-associated Variants on Clinicopathologic Variables in 5,895 Prostate Cancer Patients (2009) (1)
- A MULTICENTER PILOT STUDY TO ASSESS THE FEASIBILITY OF THE RFT [trade mark sign] SYSTEM IN MEN WITH SYMPTOMATIC BPH (1999) (1)
- MP46-05 DEVELOPMENT OF A CLINICAL IMPLEMENTATION PLAN (CAREPATH) FOR A NOVEL URINE EXOSOME GENE EXPRESSION ASSAY AS PART OF A TWO-COHORT, ADAPTIVE DECISION IMPACT UTILITY TRIAL (2018) (1)
- Workshop on prostate markers (1998) (1)
- COMMENT ON: THE CLINICAL USEFULNESS OF PROSTATE SPECIFIC ANTIGEN : UPDATE 1994. AUTHORS' REPLY (1996) (1)
- Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CA. (2007) (1)
- MP63-14 MULTICENTER VALIDATION STUDY OF A TISSUE METHYLATION ASSAY TO PREDICT HISTOPATHOLOGICALLY CANCER-NEGATIVE REPEAT PROSTATE BIOPSIES (2014) (1)
- Prostate cancer (PC)-management of 669 cases in Ghana West Africa (2014) (1)
- In Reply (2019) (1)
- targeted 18 F-DCFPyL PET / CT in the Preoperative Staging of Men with High-risk Prostate Cancer : Results of a Prospective Phase II Single-Center Study (2017) (1)
- 957: Validity of Complexed Prostate Specific Antigen (CPSA) for the Diagnosis of Biochemical Recurrence after Radical Retropubic Prostatectomy (2005) (1)
- [-2]PROPSA FOR PROSTATE CANCER DETECTION: A PROSPECTIVE, MULTICENTER, NCI EARLY DETECTION RESEARCH NETWORK STUDY (2009) (1)
- PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME (PSADT), GLEASON SCORE AND THE TIME TO PSA RECURRENCE FOLLOWING RADICAL PROSTATECTOMY PREDICTS TIME TO DISTANT PROGRESSION (1999) (1)
- Abstract 3640: Overexpression of five novel biomarkers in human prostate tissues and cell lines (2012) (1)
- Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial. (2021) (1)
- Multiple Intermediate-Risk Factors as a Prognostic Tool for Men With Localized Prostate Cancer (2014) (1)
- Letter-from-the-editor for the January 2005 issue of UROLOGY (2005) (1)
- 1434: Predicting the Need for Treatment among Men with Low Grade, Low Stage Prostate Cancer Enrolled in a Program of Expectant Management with Curative Intent (2007) (1)
- Factors influencing prostate cancer specific mortality in patients receiving delayed androgen deprivation therapy for metastasis after biochemical recurrence following radical prostatectomy. (2006) (1)
- VALIDATING THE PARTIN TABLES USING THE NCI SEER DATABASE (2009) (1)
- 624Preoperative serum GSTP1 CPG island hypermethylation predicts the risk of early PSA recurrence following radical prostatectomy (2005) (1)
- The prostate-localized kallikreins: Prostate specific antigen and human kallikrein 2 (1999) (1)
- EVALUATION OF AN ARTIFICIAL NEURAL NETWORK FOR THE DETERMINATION OF THE PROBABILITY OF PROSTATE CANCER PRIOR TO BIOPSY (1999) (1)
- Open versus minimally invasive radical prostatectomy. (2010) (1)
- 1191: Survival Following Hormonal Therapy: Men who Develop Metastasis More than Five Years Following Radical Prostatectomy Live Longer (2006) (1)
- 2040 OBESITY AND PROSTATE ENLARGEMENT IN MEN WITH LOCALIZED PROSTATE CANCER (2011) (1)
- 474: Pathologic Outcomes and Biochemical Progression in Men with T1C Prostate Cancer Undergoing Radical Prostatectomy with PSA 2.6-4.0 ng/ml Versus PSA 4.1-6.0 ng/ml (2006) (1)
- MP53-04 SIGNIFICANT INTER-INSTITUTIONAL VARIATIONS IN RACIAL DISPARITIES AMONG AFRICAN-AMERICAN MEN ELIGIBLE FOR PROSTATE CANCER ACTIVE SURVEILLANCE (2015) (1)
- A prospective comparative study of routine versus deferred pelvic drain placement after radical prostatectomy: impact on complications and opioid use (2020) (1)
- BODY MASS INDEX AND PROSTATE-SPECIFIC ANTIGEN AS A PREDICTOR OF ADVERSE PATHOLOGY AND BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY (2009) (1)
- Letter from the editor: Urology (1998) (1)
- The Role of Complexed Prostate-Specific Antigen in Prostate Cancer Screening (2008) (1)
- RATIO OF SERUM PRO-PSA TO FRACTION SERUM FREE PSA PREDICTS THE NEED FOR TREATMENT AMONG MEN WITH LOW GRADE, LOW STAGE PROSTATE CANCER ENROLLED IN AN EXPECTANT MANAGEMENT PROGRAM (2009) (1)
- 645: Biopsy Indication - A Predictor of Pathological Stage Among Men with Pre-Operative Serum PSA Levels <4.0 NG/ML and T1C Disease (2004) (1)
- PSA KINETICS ALONE ARE AN UNRELIABLE TRIGGER FOR INTERVENTION IN A PROSTATE CANCER SURVEILLANCE PROGRAM (2009) (1)
- PROGRESSION OUTCOMES AFTER RADICAL PROSTATECTOMY FOR MEN IN THEIR 30'S COMPARED TO OLDER MEN (2008) (1)
- Molecular forms of PSA: What does the future hold? (2003) (1)
- Focal therapy for prostate cancer. (2008) (1)
- Clinical management of rising prostate-specific antigen after radical retropubic prostatectomy (2005) (1)
- CONTINUING RESULTS OF A MULTI-CENTER TRIAL OF A NEW GENERATION COOLED TRANS URETHRAL MICROWAVE THERAPY FOR BENIGN PROSTATIC HYPERPLASIA (2008) (1)
- 174 A PHASE II RANDOMIZED CONTROLLED TRIAL OF POMX VS. PLACEBO PRIOR TO RADICAL PROSTATECTOMY (2012) (1)
- 1626: Surveillance of Men with Low Grade and Stage Prostate Cancer Enrolled in an Expectant Management Program: Changes in Clinical, Pathological and Nuclear Morphometry Patterns Observed Over Time (2007) (1)
- Best of the 2015 AUA Annual Meeting: Highlights From the 2015 American Urological Association Annual Meeting, May 15-19, 2015, New Orleans, LA. (2015) (1)
- THE SIGNIFICANCE OF POSITIVE BLADDER NECK MARGINS AFTER RADICAL PROSTATECTOMY (2009) (0)
- Minimally Invasive Procedures in Urology (2005) (0)
- What you can learn from percent free PSA testing (2000) (0)
- PD13-06 EFFECT OF PHARMACOLOGIC PROPHYLAXIS ON VENOUS THROMBOEMBOLISM AFTER RADICAL PROSTATECTOMY: THE PREVENTER RANDOMIZED CLINICAL TRIAL (2020) (0)
- The Lance Armstrong Effect (2009) (0)
- Treatment of locally advanced and metastatic prostate cancer (2008) (0)
- Subject Index Vol. 85, 2010 (2010) (0)
- PROSTATE CANCER SAMPLED ON SEXTANT NEEDLE BIOPSY: THE SIGNIFICANCE OF CANCER IN DIFFERENT AREAS OF THE PROSTATE (1999) (0)
- High "phi"ve. (2018) (0)
- Prostate-specific antigen as a marker of disease activity in prostate cancer. (2002) (0)
- Serum Markers and Screening (2009) (0)
- 987 CRITICAL ASSESSMENT OF URINARY PROSTATE CANCER GENE 3 (PCA3) IN THE PREDICTION OF AGGRESSIVE PROSTATE CANCER (GLEASON SCORE ≥ 7) AT BIOPSY (2011) (0)
- Expectant management of prostate cancer. (2003) (0)
- Cyclooxygenase-2 as a marker for prostate cancer. (2001) (0)
- Machine Learning for the Prediction of Lymph Node Metastasis in Patients with Prostate Cancer (2022) (0)
- Original Articles BIOLOGICAL AGGRESSIVENESS OF HEREDITARY PROSTATE CANCER: LONG-TERM EVALUATION FOLLOWING RADICAL PROSTATECTOMY (1998) (0)
- Analysis of Smooth Muscle and Collagen Subtypes in the Normal Newborn and Bladder Exstrophy Patient (1999) (0)
- A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization (2020) (0)
- BPH Plus Prostate Cancer Therapy and Markers Featured at EAU: Highlights from the 14th Annual Congress of the European Association of Urology April 7-10, 1999, Stockholm, Sweden. (1999) (0)
- Best of the 2014 AUA Annual Meeting: Highlights From the 2014 American Urological Association Annual Meeting, May 16-21, 2014, Orlando, FL. (2014) (0)
- MP60-03 ISOPSA: CLINICAL PERFORMANCE OF A SINGLE PARAMETER, STRUCTURE BASED TEST FOR HIGH GRADE PROSTATE CANCER IN A LARGE, MULTICENTER, PROSPECTIVE VALIDATION TRIAL (2021) (0)
- Postprostatectomy risk stratification based on detection of occult lymph node metastasis. (2007) (0)
- Tissue changes in prostate zones of men undergoing long-term finasteride therapy for BPH (1997) (0)
- “Lessons learnt in a decade as ‘Editor‐in‐Chief ’ . . .” (2008) (0)
- Cell Cycle Progression Score, but Not Phosphatase and Tensin Homolog Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-risk Prostate Cancer in Men Treated With and Without Salvage Radiotherapy (2022) (0)
- 367 LONG-TERM SURVIVAL OUTCOME IN MEN WITH FOCAL VERSUS ESTABLISHED EXTRAPROSTATIC EXTENSION IN A LARGE RADICAL PROSTATECTOMY SERIES (2013) (0)
- Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer : Part 1 Review (2017) (0)
- PD42-05 GROUPING GLEASON SCORE 8 AND GLEASON SCORE 9-10 PROSTATE CANCER AS A SINGLE ENTITY RISKS LOSING PROGNOSTIC INFORMATION FOR MORTALITY (2016) (0)
- Sildenafil Does not Improve Sexual Function in Men Without Erectile Dysfunction but Does Reduce the Postorgasmic Refractory Time (2006) (0)
- Biomarkers and Risk Factors Impact of Body Mass Index on Biochemical Recurrence Rates After Radical Prostatectomy: An Analysis Utilizing Propensity Score Matching (2008) (0)
- PD34-07 NATURAL HISTORY OF PROGRESSION TO PSA RECURRENCE AND METASASIS AMONG AT RISK MEN FOLLOWING RADICAL PROSTATECTOMY (2014) (0)
- Treatment options for localized prostate cancer (2008) (0)
- MP13-06 MULTICENTER CLINICAL TRIAL OF REAL-TIME PROSTATE CANCER DIAGNOSIS USING OPTICAL SPECTROSCOPY GUIDED PROSTATE BIOPSY (2019) (0)
- Predicting prostate cancer specific mortality following biochemical recurrence after radical prostatectomy (2005) (0)
- 128 Serum concentrations of human glandular kallikrein 2 (HK2) but not free PSA, total PSA or %FPSA permit discrimination of pathologically organ-confined (OC) from non-organ confined (NOC), non-palpable (clinical stage T1C) prostate cancer (2004) (0)
- PD10-02 ADJUVANT RADIATION WITH ANDROGEN DEPRIVATION THERAPY FOR MEN WITH LYMPH NODE METASTASES FOLLOWING RADICAL PROSTATECTOMY: IDENTIFYING MEN WHO BENEFIT (2018) (0)
- MP70-07 THE EFFECT OF ADDITIONAL PATHOLOGIC FEATURES ON CANCER SPECIFIC SURVIVAL FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH SEMINAL VESICLE INVASION (2014) (0)
- Introduction to urology online (1999) (0)
- The impact of DNA methylation on the identification of recurrent prostate cancer (2007) (0)
- Prognostic factors for prostate cancer: Introduction (1998) (0)
- MP60-16 CELL CYCLE PROGRESSION SCORE AND PTEN AS PROGNOSTIC FACTORS FOR METASTASIS IN INTERMEDIATE AND HIGH RISK PROSTATE CANCER OVERALL, AND IN THOSE WHO RECEIVED SALVAGE RADIOTHERAPY (2021) (0)
- 1659: Effects of Finasteride and Saw Palmetto on BPSA, Propsa, and cPSA in Men with Benign Prostatic Hyperplasia (2004) (0)
- IsoPSA Performance Characteristics Are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results from the IsoPSA Validation Study. (2023) (0)
- Prostate Cancer Bisphosphonates in Metastatic Prostate Cancer A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients with Hormone-Refractory Metastatic Prostate Carcinoma News and Views from the Literature (2003) (0)
- INTERIM RESULTS OF A NOVEL ‘ADAPTIVE’ REGISTRATION‐UTILITY TRIAL ASSESSING THE PERFORMANCE OF EXODX® (PROSTATE) INTELLISCORE (EPI); A NON‐DRE URINE EXOSOME GENE EXPRESSION ASSAY TO PREDICT HIGH GRADE DISEASE ON INITIAL BIOPSY.: PNFLBA‐15 (2017) (0)
- 1278: Obesity is a Predictor of Increased Prostate Volume (2005) (0)
- Erratum: Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score (BJU Int (2011) 107 (15621569)) (2011) (0)
- Best of the 2012 AUA Annual Meeting: Highlights From the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA. (2012) (0)
- 933 PSA FREE OUTCOMES AFTER RADICAL PROSTATECTOMY AMONG MEN INITIALLY MANAGED WITH ACTIVE SURVEILLANCE FOR PROSTATE CANCER: JOHNS HOPKINS EXPERIENCE (2010) (0)
- PLOIDY ANALYSIS AS A PREDICTOR OF RADICAL PROSTATECTOMY FOR STAGE T2 DISEASE (1995) (0)
- Prostate Cancer Open Versus Minimally Invasive Radical Prostatectomy (2010) (0)
- A New Source for Your Patient-oriented Education (2013) (0)
- Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. (2002) (0)
- Review and synopsis of: Radical prostatectomy for clinical stage T3a disease (2007) (0)
- 843: Early Alterations in Nuclear Structure of Normal Appearing Prostate Epithelium in a Cancerous Prostate Predict Bone Metastasis Following Biochemical Recurrence (2004) (0)
- SERUM PROSTATE-SPECIFIC ANTIGEN AS A BIOMARKER FOR DISEASE PROGRESSION IN BENIGN PROSTATIC HYPERPLASIA * (2003) (0)
- Radical radiotherapy for squamous carcinoma of the larynx, oropharynx, hypopharynx: Patterns of recurrence, treatment and survival (1997) (0)
- MP1-11 VALIDATION OF THE DECIPHER® PROSTATE CANCER CLASSIFIER IN INTERMEDIATE TO HIGH RISK MEN TREATED WITH RADICAL PROSTATECTOMY BUT WITHOUT ADDITIONAL THERAPY UPON PSA RISE (2015) (0)
- CORRELATION BETWEEN QUANTITATIVE TISSUE PROSTATE SPECIFIC ANTIGEN (PSA) IMMUNOHISTOCHEMISTRY (IHC) AND SERUM LEVELS OF PSA (1999) (0)
- [Resveratrol and newly synthetized resveratrol analogs in therapy of prostate carcinoma]. (2007) (0)
- Nomograms That May Aid in Treatment Decisions (1997) (0)
- MINI-LAP RADICAL RETROPUBIC PROSTATECTOMY: TECHNIQUES AND RESULTS (1999) (0)
- 1 Serum Markers and Screening (2009) (0)
- MP22-14 DEFINITIVE THERAPY FOR MEN WITH NEWLY-DIAGNOSED OLIGOMETASTATIC PROSTATE CANCER: INITIAL SURGICAL OUTCOMES FROM A PHASE II STUDY (2018) (0)
- Letter from the editor. (2001) (0)
- Prostate cancer update: 2004: highlights from the 4th international prostate cancer congress, grand bahama island, bahamas, july 15-18, 2004. (2005) (0)
- Multivariate models for predicting pathologic stage (2005) (0)
- Cytoplasmic Induction and Over-expression of Cyclooxygenase-2 in Human Prostate Cancer: Implications for Prevention (2001) (0)
- 667: Pathological and Biochemical Outcomes after Radical Prostatectomy for Men with a Biopsy Gleason Score of 8 to 10 (2006) (0)
- 2206 THE NCI EARLY DETECTION RESEARCH NETWORK (EDRN) URINARY PCA3 VALIDATION TRIAL (2012) (0)
- 397Clinical and pathological outcome after radical prostatectomy for prostate cancer with a preoperative gleason score 8 to 10 (2005) (0)
- 1560 ISOLATED SINGLE CORE HIGH GRADE PROSTATIC ADENOCARCINOMA IS ASSOCIATED WITH INCREASED RISK FOR EXTRAPROSTATIC EXTENSION, SEMINAL VESICLE INVASION AND POSITIVE MARGIN STATUS ON RADICAL PROSTATECTOMY (2010) (0)
- Lotan and De Marzo et al 1 PTEN Protein Loss by Immunostaining : Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients (2011) (0)
- PROSTATE BIOPSY OUTCOME PREDICTION – COMPARISON OF A NOVEL LOGISTIC REGRESSION-BASED MODEL, THE PROSTATE CANCER RISK CALCULATOR AND PSA ALONE (2008) (0)
- 1416: Serum Leptin Does not Predict Pathological Stage Among Men Treated with Radical Prostatectomy (2005) (0)
- Multiplexed Analysis of Circulating Prostate Tumor and Host Response Markers (2005) (0)
- FURTHER CHARACTERIZATION OF A HUMAN NUCLEAR MATRIX PROTEIN (B23) AS A MARKER FOR PROSTATE CANCER: CORRELATION WITH TUMOR GRADE AND STAGE (1999) (0)
- 137 EVALUATION OF [-2]PROPSA IN COMBINATION WITH PSA AND FREE PSA, USING THE BECKMAN COULTER ACCESS IMMUNOASSAY SYSTEMS, FOR IDENTIFYING PATIENTS WITH AGGRESSIVE PROSTATE CANCER. A MULTI-CENTER PROSPECTIVE CLINICAL EVALUATION (2010) (0)
- ClariCore™ Optical Biopsy System for Prostate Cancer Diagnosis: Preliminary Results from a Multicenter Clinical Trial (2017) (0)
- Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer : Part 2 (2017) (0)
- 1354 PRE-OPERATIVE PREDICTORS OF EARLY BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY (2013) (0)
- Abstract397Clinical and pathological outcome after radical prostatectomy for prostate cancer with a preoperative gleason score 8 to 10 (2005) (0)
- Abstract 2731: Serum prostate health index and biopsy tissue DNA content at the time of diagnosis predicts the need for treatment in men enrolled in an active surveillance program (2010) (0)
- 354 OBESITY AND LONG TERM SURVIVALS AFTER RADICAL PROSTATECTOMY IN A SINGLE TERTIARY REFERRAL CENTER (2013) (0)
- Fatty Acid Synthase as a biomarker in prostate cancer: a high-throughput quantitative image analysis (2008) (0)
- Review Article THE EVOLVING ROLE OF DOCETAXEL IN THE MANAGEMENT OF ANDROGEN INDEPENDENT PROSTATE CANCER (2003) (0)
- Urological Emergencies: A Practical Guide (2006) (0)
- 431 Validation of the Decipher® prostate cancer classifier in intermediate to high risk men treated with radical prostatectomy but without additional therapy upon PSA rise (2015) (0)
- Prostate-Cancer Risk Stratification via Early PSA Testing. (2007) (0)
- Long term efficacy of the express targis cooled thermotherapy compared with the original treatment for benign prostatic hyperplasia (2001) (0)
- No differences in PSA failure rates following radical prostatectomy between men with pT2a AND pT2b tumors (2004) (0)
- 675: Body Mass Index and Outcomes in African-American and Caucasian Men Following Radical Prostatectomy for Clinically Localized Prostate Cancer (2005) (0)
- Title: 18 F-DCFBC PET/CT for PSMA-based Detection and Characterization of Primary Prostate Cancer F-DCFBC Imaging of Primary Prostate Cancer (2015) (0)
- 257: Stronger Association between Obesity and Biochemical Progression Following Radical Prostatectomy over Time (2005) (0)
- The Clinical Management of Prostate Cancer — The Surgeon's Approach and Outcomes (2003) (0)
- Prostate Cancer Obesity and Prostate Cancer Detection and Progression Body Mass Index and Risk of Prostate Cancer In U.S. Health Professionals News and Views from the Literature (2004) (0)
- Prostate biopsy schemes and the detection of prostate cancer. (1999) (0)
- MP53-17 CLINICAL VALIDATION OF THE 2005 ISUP GLEASON GRADING SYSTEM IN A COHORT OF INTERMEDIATE AND HIGH RISK MEN UNDERGOING RADICAL PROSTATECTOMY (2015) (0)
- Long-term survival after radical nephrectomy with intrahepatic or supradiaphragmatic intracaval thrombectomy for renal cell carcinoma (1997) (0)
- 263 Development of novel PCA3 cut-offs for initial and repeat biopsy using different statistical approaches within a US-European multi institutional cohort (2012) (0)
- 305 EVOLUTION OF THE CLINICAL PRESENTATION OF MEN UNDERGOING RADICAL PROSTATECTOMY FOR HIGH-RISK PROSTATE CANCER (2011) (0)
- 1412: Impact of Delayed Intervention after Radical Prostatectomy on Cancer Control in Patients with High-Risk, Locally Advanced Adenocarcinoma of the Prostate (2007) (0)
- Workshop on Prostate Markers. International Union Against Cancer. (1998) (0)
- Proliferation and apoptosis in seminal vesicles compared to the prostate (1999) (0)
- Letter from the editorLetter from the editor (2000) (0)
- PSA Report Card (2007) (0)
- RE: BIOLOGICAL AGGRESSIVENESS OF HEREDITARY PROSTATE CANCER (1999) (0)
- Letter from the editor [1] (1999) (0)
- MP4-13 CONDITIONAL CANCER SPECIFIC SURVIVAL FOLLOWING RADICAL PROSTATECTOMY DEPENDS ON PREOPERATIVE RISK CLASSIFICATION (2015) (0)
- Machine Learning for the Prediction of Distant Metastases Following Postprostatectomy Salvage Radiation Therapy (2022) (0)
- Active Surveillance in 2020: A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for Active Surveillance (2020) (0)
- Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA. (2013) (0)
- Clinical Performance of the ExoDx (EPI) Prostate Intelliscore Test to Predict High-grade Prostate Cancer at Initial Biopsy: A Pooled Analysis of Three Independent Prospective Studies. (2020) (0)
- MP61-11 SPINK1 DEFINES A MOLECULAR SUBTYPE OF PROSTATE CANCER MEN WITH MORE RAPID PROGRESSION FROM BIOCHEMICAL RECURRENCE TO DEATH IN AN AT RISK, NATURAL HISTORY COHORT (2015) (0)
- PD60-05 PROSPECTIVE VALIDATION OF THE ISOPSATM ASSAY FOR DETECTION OF HIGH GRADE PROSTATE CANCER (2018) (0)
- 851: Early Prostate Cancer Antigen and Prostate Specific Antigen: Two is better than One (2006) (0)
- DETECTION AND CHARACTERIZATION OF CIRCULATING PROSTATE CANCER CELLS: A POTENTIAL CLINICAL TOOL FOR THE MANAGEMENT OF ADVANCED PROSTATE CANCER (1999) (0)
- Re : The Relationship between the Extent of Extraprostatic Extension and Survival following Radical Prostatectomy (2015) (0)
- Prostate Cancer Early Hormonal Therapy for Prostate Cancer: The Good, the Bad, and the Ugly Early Delayed Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomy News and Views from the Literature (2005) (0)
- COMBINATION OF FIVE SNPs PREDICTS INDIVIDUAL RISK FOR PROSTATE CANCER (2008) (0)
- 5-YEAR RESULTS OF A MULTI-CENTER STUDY OF COOLED THERMOTHERAPY FOR BENIGN PROSTATIC HYPERPLASIA (2009) (0)
- MP12-03 FAVORABLE INTERMEDIATE-RISK PROSTATE CANCER LEADS TO WORSE SURVIVAL COMPARED TO LOW-RISK PATIENTS DUE TO ADVERSE PATHOLOGY (2018) (0)
- The predictive capability of prostate-specific antigen kinetics. (2006) (0)
- PSA doubling time (PSADT) ≤6 months to identify a subgroup of men with biochemically-recurrent prostate cancer (BRPC) after prostatectomy (RP) at highest risk of distant metastasis (dMET). (2016) (0)
- General considerations affecting treatment options for patients with prostate cancer (2008) (0)
- Modulation of EPCA-2 Levels in Men with Localized Prostate Cancer Treated with Radiation with or without Androgen Suppression Therapy (2008) (0)
- V11-02 DYNAMIC UMBILICAL LIGAMENT ANASTOMOTIC SLING DURING RALRP: A PILOT STUDY (2019) (0)
- NEOADJUVANT AND ADJUVANT alpha-BLOCKADE TO IMPROVE EARLY RESULTS OF HIGH-ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY (TUMT): RESULTS OF A PROSPECTIVE, RANDOMIZED CLINICAL TRIAL (1999) (0)
- 2051 SERUM PROSTATE HEALTH INDEX AND BIOPSY TISSUE DNA CONTENT AT THE TIME OF DIAGNOSIS PREDICTS THE NEED FOR TREATMENT IN MEN ENROLLED IN AN ACTIVE SURVEILLANCE PROGRAM (2010) (0)
- Best of the 2019 AUA Annual Meeting: Highlights From the 2019 American Urological Association Annual Meeting, May 3-6, 2019, Chicago, IL. (2019) (0)
- Prostate Cancer Markers and Treatments Ranging From Gene Therapy to Cryosurgery Examined at AUA: Highlights from the American Urological Association 93rd Annual Meeting May 30-June 4, 1998, San Diego, Calif. (1999) (0)
- 641 CRITICAL ASSESSMENT OF URINARY PROSTATE CANCER GENE 3 (PCA3) IN THE PREDICTION OF AGGRESSIVE PROSTATE CANCER (GLEASON score ≥ 7) AT BIOPSY (2011) (0)
- PREDICTION OF MORTALITY FOLLOWING RADICAL PROSTATECTOMY BY CHARLSON COMORBIDITY INDEX (2008) (0)
- Does laterality of positive needle biopsy in clinical T2a prostate cancer patients affect biochemical recurrence free survival? (2009) (0)
- 192 IMPLICATIONS OF SURGICAL MARGIN STATUS ON PROSTATE CANCER-SPECIFIC SURVIVAL (2011) (0)
- 2323 [-2]PROPSA PREDICTS BIOPSY RECLASSIFICATION IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER (2011) (0)
- The natural history of progression to PSA recurrence and metastasis among at risk men following radical prostatectomy. (2014) (0)
- 767 PATHOLOGICAL AND ONCOLOGIC OUTCOMES FOR MEN WITH POSITIVE LYMPH NODES AT RADICAL PROSTATECTOMY: 30-YEAR EXPERIENCE FROM A SINGLE INSTITUTION (2012) (0)
- 1712: Evaluation of the Utility of Early Prostate Cancer Antigen (EPCA) Expression as a Predictor of the Presence of Prostate Cancer in Men with Histologically Negative Biopsies (2007) (0)
- Decision tree algorithms for prostate cancer detection Complexed PSA and other significant predictors using CHAID analysis (2002) (0)
- MP53-02 IS CLINICAL STAGE T2C PROSTATE CANCER INTERMEDIATE OR HIGH-RISK DISEASE? (2015) (0)
- Preliminary evaluation of 18F-DCFBC PSMA PET for detection of primary prostate cancer (2013) (0)
- From the Editors (2015) (0)
- PROSPECTIVE MULTICENTER COMPARISON OF OPEN AND ROBOTIC RADICAL PROSTATECTOMY: THE PROST‐QA/RP2 CONSORTIUM: PD18‐08 (2017) (0)
- of Tissue Microarrays in the Evaluation of Focal Alterations of bcl-2 and p53 in Whole Mount Derived Prostate Tissues Vasectomy and Prostate Cancer (2006) (0)
- New serum tests for the diagnosis of prostate cancer. (2001) (0)
- 860: Protein C Inhibitor as a Biomarker for Prostate Cancer: Detection, Staging, and Prediction of Recurrence (2006) (0)
- Abstract 4451: The NCI Early Detection Research Network (EDRN) urinary PCA3 validation trial (2012) (0)
- Combined DNA-methylation intensity and clinical risk score to stratify patients for high-grade disease. (2016) (0)
- Best of the AUA Annual Meeting: Highlights From the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC. (2011) (0)
- Preoperative SerumDNA GSTP 1 CpG Island Hypermethylation and the Riskof Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy (2005) (0)
- PSA levels of >1.5-4 ng/mL in a men’s health evaluation as a method for informed decision making. (2015) (0)
- Positive LymphNodes at Radical Prostatectomy : The JohnsHopkinsHospital 30-Year Experience (2013) (0)
- 394: Overall Survival of men Undergoing Radical Prostatectomy (2007) (0)
- Best of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL. (2008) (0)
- 299 A CONTEMPORARY ANALYSIS OF CLINICAL OUTCOMES FOR MEN WITH ADENOCARCINOMA OF THE PROSTATE WITH SEMINAL VESICLE INVASION (PT3B) AFTER RADICAL PROSATECTOMY (2010) (0)
- Clinical predictors of organ-confined prostate cancer (2007) (0)
- IL-3 PSA Update-2004 (2004) (0)
- PrognosticValueofPreoperativeSerumCell-FreeCirculatingDNAin MenwithProstateCancerUndergoingRadicalProstatectomy (2007) (0)
- ERG Status at the Margin is Associated with Biochemical Recurrence after Radical Prostatectomy with Positive Surgical Margins. (2023) (0)
- What ’ s known on the subject ? and What does the study add ? (2013) (0)
- Prostate-specific antigen (PSA) after anatomic radical retropubic prostatectomy: Long-term results in 1623 patients (1997) (0)
- PD15-02 LONG-TERM HEALTH RELATED QUALITY OF LIFE IN PROSTATE CANCER PATIENTS REQUIRING RADIOTHERAPY AFTER RADICAL PROSTATECTOMY (2023) (0)
- MP45-11 EFFECT OF ERYTHROPOIETIN ON ERECTILE FUNCTION AFTER RADICAL PROSTATECTOMY: THE ERECT RANDOMIZED CLINICAL TRIAL (2020) (0)
- Critical analysis of false elevations in PSA results reported with the abbott AxSYM assay (1999) (0)
- CLINICAL EFFECTS OF SAW PALMETTO EXTRACT IN MEN WITH SYMPTOMATIC BPH (1999) (0)
- The Scientific Basis of Urology, Second Edition (2005) (0)
- Optimal surgical management of the obese man with prostate cancer: laparoscopic or perineal radical prostatectomy. (2005) (0)
- Multidisciplinary clinic evaluation changes prostate cancer stage and risk stratification. (2014) (0)
- 467: Natural History of Progression to Distant Metastasis after Failure to Achieve an Undetectable PSA Following Radical Prostatectomy (2005) (0)
- PROSTATE HEALTH INDEX DENSITY IMPROVES DETECTION OF CLINICALLY‐SIGNIFICANT PROSTATE CANCER: PD71‐02 (2017) (0)
- Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer : Part 2 Review (2017) (0)
- Reply by Authors. (2022) (0)
- 288: Quantitative Nuclear Grade (QNG) Assessment of Non-Invasive Papillary Urothelial Neoplasms (2004) (0)
- 379: A Critical Analysis of the Interpretation of Biochemical Recurrence in Surgically Treated Patients using the Revised ASTRO Criterion–"NADIR +2" (2007) (0)
- Subfractions and Derivatives of Total Prostate-Specific Antigen in the Early Detection of Prostate Cancer (2009) (0)
- Highlights from the 20th International Prostate Cancer Update (2010) (0)
- Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection (2023) (0)
- Imaging utilization for the staging of clinically localized prostate cancer. (2011) (0)
- Abstract 129: Biobanking and feasibility considerations for prostate cancer gastrointestinal microbiome studies (2018) (0)
- ncology xternal Validation of University of alifornia , San Francisco , Cancer of the rostate Risk Assessment (2008) (0)
- In Reply: Clinical and Biological Characteristics of Familial Benign Prostatic Hyperplasia (1997) (0)
- 1210 BIOPSY-SPECIFIC PCA3- BASED PROSTATE BIOPSY NOMOGRAMS ARE HIGHLY ACCURATE (2012) (0)
- 911 Biopsy-specific PCA3-based prostate biopsy nomograms are highly accurate (2012) (0)
- Contents Vol. 85, 2010 (2010) (0)
- PD30-05 THE IMPACT OF DOWNGRADING FROM BIOPSY GLEASON SCORE 7 TO RADICAL PROSTATECTOMY GLEASON SCORE 6 ON BIOCHEMICAL RECURRENCE (2016) (0)
- CAUSES, TIMING, AND HOSPITAL COSTS OF INDEX VS. NON‐INDEX HOSPITAL READMISSIONS FOLLOWING RADICAL PROSTATECTOMY: IMPLICATIONS FOR COST CONTAINMENT STRATEGIES: PD32‐08 (2017) (0)
- Combined Use of Tissue Morphology, Neural Network Analysis of Chromatin Texture and Clinical Variables to Predict Prostate Cancer Agressiveness from Biopsy Water (1999) (0)
- SURVIVAL OUTCOMES IN SEPTUAGENARIANS AND OCTOGENARIANS AFTER RADICAL PROSTATECTOMY (2009) (0)
- Advances in prostate cancer treatment: highlights from the 2nd international prostate cancer congress, st. Thomas, u.s. Virgin islands, july 17-20, 2002. (2003) (0)
- 849: Preoperative Serum Concentration of Cell-Free Circulating Cancer DNA in Patients with Prostate Cancer and the Risk of Recurrence after Radical Prostatectomy (2006) (0)
- PROSTATIC ADENOCARCINOMA WITH DUCTAL FEATURES DIAGNOSED ON NEEDLE BIOPSY (NBx): A CLINICOPATHOLOGIC STUDY WITH RADICAL PROSTATECTOMY (RP) CORRELATION (1999) (0)
- Pooled analysis of >1000 patients enrolled in two independent prospective validation studies show consistent performance of a urine exosome gene expression assay to rule-out benign and low-grade prostate cancer at initial biopsy (2019) (0)
- 401 UTILITY OF PSA VELOCITY FOR PREDICTION OF GLEASON SCORE UPGRADING BETWEEN BIOPSY AND RADICAL PROSTATECTOMY (2010) (0)
- 2320 INITIAL AND REPEAT PROSTATE BIOPSY: COMPARATIVE PERFORMANCE ANALYSIS OF PSA, %FPSA, PROSTATE VOLUME AND URINARY PCA3 INCLUDING DEVELOPMENT OF NOVEL PCA3 CUT-OFF THRESHOLDS (2011) (0)
- Abstract 452: MIC-1 and Endoglin are protein serum biomarkers capable of increasing the clinical diagnostic specificity of the PSA test (2016) (0)
- Urological oncological emergencies (2004) (0)
- Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate- and high-risk prostate cancer overall, and in those who also received salvage radiotherapy. (2021) (0)
- Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate and high-risk prostate cancer. (2019) (0)
- A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy (2016) (0)
- 1411: Serum Biomarker Discovery using Proteomics Approaches to Predict Prostate Cancer Recurrence (2005) (0)
- PREDICTING PATHOLOGICAL STAGE OF LOCALIZED PROSTATE CANCER. AUTHORS' REPLY (1997) (0)
- Serum prostate-specific antigen as a biomarker for benign prostatic hyperplasia disease progression: Introduction (2003) (0)
- Though unemployment throughout the region declined in March, Caroline's dropped the farthest from February to March. (2011) (0)
- Current Clinical Applications of the 111 In-capromab Pendetide Scan (ProstaScint ® Scan, Cyt-356) (2001) (0)
- VARIANTS IN GENES INVOLVED IN THE IMMUNE RESPONSE AND OXIDATION AND SUBSEQUENT RISK OF PROSTATE CANCER RECURRENCE (2009) (0)
- 613: Natural History of Organ-Confined, Gleason ≤6 Prostate Cancer Following Radical Prostatectomy (RP) (2007) (0)
- 1003 IMPACT OF SURGICAL TECHNIQUE (OPEN VS. LAPAROSCOPIC VS. ROBOTIC-ASSISTED) ON PATHOLOGICAL AND BIOCHEMICAL OUTCOMES FOLLOWING RADICAL PROSTATECTOMY: AN ANALYSIS USING PROPENSITY SCORE MATCHING (2011) (0)
- Survival following early hormone therapy for men with rapid PSA doubling time within 2 years following radical prostatectomy. (2009) (0)
- 392: Novel Risk Classification Model for Recurrencefollowing Radical Prostatectomy (RP) (2007) (0)
- Assessment of high-grade prostate cancer risk using prostate cancer biomarkers. (2020) (0)
- 2297 NOVEL BIOMARKERS FOR AGGRESSIVE PROSTATE CANCER (2011) (0)
- Best of the AUA Annual Meeting (2011) (0)
- Running Foot: 18 F-DCFBC Imaging of Primary Prostate Cancer (2015) (0)
- 840: Prospective Comparison of the “Kattan Nomogramms” Versus “Artificial Neural Networks” (ANN) for Predicting Pathological Stage and Disease Progression of Patients with Clinically Localized Prostate Cancer (PCA) (2004) (0)
- DOES ANGIONGENESIS (MICROVESSEL DENSITY) OF PROSTATE CARCINOMA DIAGNOSED ON NEEDLE BIOPSY CORRELATE WITH RADICAL PROSTATECTOMY STAGE (1999) (0)
- What is the true mortality benefit of prostate-specific antigen screening? (2010) (0)
- Chromatin and cancer: Causes and consequences (2000) (0)
- Bone Integrity Affects the Natural History of Prostate Cancer (1999) (0)
- ENDOGLIN (CD105) AS A POTENTIAL URINARY MARKER FOR PROSTATE CANCER DETECTION (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Alan Wayne Partin?
Alan Wayne Partin is affiliated with the following schools:
